Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations (Unaudited)

v3.23.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Income Statement [Abstract]    
Revenue $ 921
Cost of sales 87
Gross profit 834
Operating expenses:    
Research and development 369,617 279,848
Clinical development 19,628 52,503
Selling, general and administrative 1,169,559 394,692
Total operating expenses 1,558,804 727,043
Loss from operations (1,557,970) (727,043)
Other income (expense):    
Interest income (expense), net 36,999 (1,147,012)
Fair value adjustments on convertible notes payable 404,194
Loss before income taxes (1,520,971) (1,469,861)
Income tax expense 11,819 2,159
Net loss $ (1,532,790) $ (1,472,020)
Net loss per common share, basic and diluted $ (0.18) $ (0.55)
Weighted average common shares outstanding 8,433,689 2,681,221